参麦注射液对重症肺炎患者免疫功能的影响  

Influences of Shenmai injection （参麦注射液） on immune functions in patients with severe pneumonia

作　　者：陈宁[1] 程彤[1] 申丽旻[1] 赵鹤龄[1] 

机构地区：[1]河北省人民医院重症医学科,河北石家庄050051

出　　处：《中国中西医结合急救杂志》2010年第5期302-304,共3页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

基　　金：河北省中医药管理局项目（2007143）

摘　　要：目的 观察在常规抗感染等西医支持治疗基础上加用参麦注射液对危重症患者免疫功能的影响.方法 将入住重症监护病房（ICU）的40例重症肺炎患者随机分为对照组和治疗组,每组20例.两组患者均给予常规抗感染等支持治疗,治疗组在常规治疗基础上加用参麦注射液80 ml加入5%葡萄糖注射液100 ml静脉滴注,每日1次,连用14 d.治疗前后分别测定两组患者外周血中免疫球蛋白（IgA、IgG、IgM）、补体C3、C4含量及T淋巴细胞亚群（CD3、CD4、CD8、CD4/CD8比值）、自然杀伤细胞（NK细胞）的活性.结果 与治疗前比较,治疗组治疗后7 d、14 d IgM、C3、CD3、CD4、NK细胞及14 d CD4/CD8比值均显著升高,且明显高于对照组[IgM：7 d时（1 130±640）mg/L比（870±520）mg/L,14 d时（1 460±780）mg/L比（900±630）mg/L;C3：7 d时（1.17±0.29）g/L比（0.92±0.46）g/L,14 d时（1.37±0.29）g/L比（0.98±0.31）g/L;CD3：7 d时0.612±0.148比0.572±0.182,14 d时0.691±0.132比0.586±0.169,CD4：7 d时0.214±0.066比0.191±0.074,14 d时0.296±0.077比0.219±0.069;CD4/CD8比值：7 d时1.06±0.87比0.87±0.56,14 d时1.10±0.77比0.90±0.62;NK细胞：7 d时0.124±0.062比0.106±0.056,14 d时0.160±0.076比0.101±0.064,均P〈0.05];两组患者治疗前后CD8、IgG、IgA、C4无明显变化（均P〉0.05）.结论 参麦注射液能显著提高危重患者免疫功能.Objective To investigate the influences of Shenmai injection （SMI, 参麦注射液） on immune functions in patients with severe pneumonia. Methods Forty patients with severe pneumonia in intensive care unit （ICU） were randomly divided into the treatment group and control group, with 20 cases in each group. Conventional anti-infectious therapy, etc. were given to the two groups, and SMI 80 ml＋ 5% glucose 100 ml intravenous drip once a day was added in the treatment group for 14 days. Before and after therapy the levels of immune globulin （IgA, IgG, IgM） and complements （C3, C4）, and the activities of T lymphocyte subsets of peripheral blood （CD3, CD4, CD8, CD4/CD8 ratio）, natural killer cell （NK cell） were detected respectively in both groups. Results Compare with the data before the treatment, the IgM, C3, CD3, CD4 and NK cell at the time points of 7 days and 14 days and CD4/CD8 ratio of 14 days were increased significantly in the treatment group, and they were obviously higher than those in the control group （IgM： 7 days （1 130±640） mg/L vs. （870±520） mg/L, 14 days （1 460±780） mg/L vs. （900±630） mg/L; C3： 7 days （1.17±0.29） g/L vs. （0. 92±0. 46） g/L, 14 days （1.37±0.29） g/L vs. （0. 98±0. 31） g/L; CD3： 7days 0.612±0.148 vs. 0.572±0.182, 14 days 0.691±0.132 vs. 0.586±0.169; CD4：7 days 0.214± 0. 066 vs. 0. 191±0. 074, 14 days 0. 296±0. 077 vs. 0. 219±0. 069; CD4/CD8 ratio： 7 days 1.06±0.87 vs. 0. 87±0. 56, 14 days 1.10±0.77 vs. 0. 90±0.62; NK cell： 7 days 0. 124±0. 062 vs. 0. 106-t-0. 056, 14 days 0. 160±0. 076 vs. 0. 101±0. 064, all P〈0. 053. After the therapy in the two groups, the CDS, IgG, IgA and C4 had no marked changes （all P〉0.05）. Conclusion SMI can improve the immune functions in patients with severe pneumonia.

关 键 词：危重症 参麦注射液 免疫功能 T淋巴细胞亚群 免疫球蛋白 

分 类 号：R285.6[医药卫生—中药学] R256.1[医药卫生—中医学]